Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Extracellular fluid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    31 result(s) found for: Extracellular fluid. Displaying page 2 of 2.
    « Previous 1  2 
    EudraCT Number: 2017-002306-12 Sponsor Protocol Number: S60382 Start Date*: 2017-09-15
    Sponsor Name:
    Full Title: Determining the role of pre-existing factors, early diagnostic options and early treatment in the development of breast cancer related lymphedema.
    Medical condition: breast cancer patients lymphedema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000013375 10025233 Lymphedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000995-41 Sponsor Protocol Number: FBX104114 Start Date*: 2007-02-20
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A double-blind, randomized, placebo-controlled multi-centre, phase II parallel dose-ranging study to assess the antifibrotic activity of GI262570 in chronic hepatitis C subjects with hepatic fibros...
    Medical condition: Chronic hepatitis C subjects with hepatic fibrosis who have failed prior antiviral therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-005707-42 Sponsor Protocol Number: A090624 Start Date*: 2007-07-23
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: A single centre phase II study of Interleukin 1 receptor antagonist in the treatment of severe Traumatic Brain Injury
    Medical condition: Severe Traumatic Brain Injury
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060690 Traumatic brain injury LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-002764-79 Sponsor Protocol Number: RESCUE Start Date*: 2023-04-13
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Diagnostic yield of Endoscopic aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr-) vs endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis ...
    Medical condition: Intraductal papillary mucinous intraductal neoplasia
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004864 10070999 Intraductal papillary mucinous neoplasm LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002935-14 Sponsor Protocol Number: EMPRA Start Date*: 2016-11-22
    Sponsor Name:Medical University of Vienna, Internal Medicine III, Clinical Div. of Nephrology and Dialysis
    Full Title: Effect of empagliflozin on the renin-angiotensin system in patients with chronic kidney disease with and without type 2 diabetes
    Medical condition: Chronic kidney disease with and without type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10076411 Chronic kidney disease stage 4 LLT
    20.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004974-16 Sponsor Protocol Number: IL1ra03 Start Date*: 2018-11-08
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: DOUBLE-BLIND PLACEBO-CONTROLLED RANDOMISED CLINICAL DOSE-RANGING STUDY TREATING MODERATE-SEVERE TRAUMATIC BRAIN INJURY PATIENTS WITH RECOMBINANT HUMAN INTERLEUKIN 1 RECEPTOR ANTAGONIST.
    Medical condition: We wish to study the drug Kineret in patients suffering from moderate-to-severe traumatic brain injury
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004863 10060690 Traumatic brain injury LLT
    20.1 10029205 - Nervous system disorders 10051288 Central nervous system inflammation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000900-15 Sponsor Protocol Number: B7A-MC-MBCU Start Date*: 2005-08-19
    Sponsor Name:Eli Lilly and Company
    Full Title: The effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography
    Medical condition: Diabetic Macular Edema (DME), is the most common cause of visual impairment in patients with diabetic retinopathy (DR). It is the accumulation of extracellular fluid in the retinal tissues of the m...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) DE (Completed) ES (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000604-16 Sponsor Protocol Number: ARD6772 Start Date*: 2006-08-30
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 (VEGF Trap) Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites.
    Medical condition: Advanced ovarian cancer patients with recurrent symptomatic malignant ascites.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001368-20 Sponsor Protocol Number: ECR-AMD-2015-09 Start Date*: 2015-09-01
    Sponsor Name:AIBILI - Association for Innovation and Biomedical Research ob Light and Image
    Full Title: A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic The...
    Medical condition: Polypoidal Choroidal Vasculopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10063381 Polypoidal choroidal vasculopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005345-36 Sponsor Protocol Number: D5610C00001 Start Date*: 2014-05-13
    Sponsor Name:Ardelyx, Inc.
    Full Title: An exploratory Phase 2, randomized, double-blind, placebo-controlled, parallel design study to evaluate the safety, tolerability, and pharmacodynamics of AZD1722 in CKD patients with type 2 diabete...
    Medical condition: Chronic kidney disease (CKD) with type 2 diabetes mellitus and albuminuria
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001377-40 Sponsor Protocol Number: MO29694 Start Date*: 2016-09-22
    Sponsor Name:Roche Farma, S.A. que representa en España a F. Hoffmann-La Roche Ltd
    Full Title: PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS.
    Medical condition: Human epidermal growth factor receptor 2 (HER2) overexpressing solid tumors specifically metastatic urothelial bladder cancer (MUBC) as well as pancreas/cholangio cancer, which are locally advanced...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033575 Pancreas cancer LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046721 Urothelial carcinoma bladder stage III LLT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SK (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 10:31:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA